Related references
Note: Only part of the references are listed.Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies
Matteo Nicola Dario Di Minno et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2021)
Hemophilia therapy: the future has begun
Pier Mannuccio Mannucci
HAEMATOLOGICA (2020)
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A
Pratima Chowdary et al.
HAEMOPHILIA (2020)
Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2
Paul Giangrande et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
A Real-World Analysis of Commonly Prescribed FVIII Products Based on US Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients
Songkai Yan et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2020)
Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
Nicola Curry et al.
HAEMOPHILIA (2019)
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Shadan Lalezari et al.
HAEMOPHILIA (2019)
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Katharine Batt et al.
JOURNAL OF BLOOD MEDICINE (2019)
Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions
Paolo A. Cortesi et al.
PHARMACOECONOMICS (2018)
Defining extended half-life rFVIIIA critical review of the evidence
J. Mahlangu et al.
HAEMOPHILIA (2018)
Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
Bernd Tischer et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates
S. von Mackensen et al.
HAEMOPHILIA (2017)
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII
M. T. Reding et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A
Paul Giangrande et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A
B. Nolan et al.
HAEMOPHILIA (2016)
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
Barbara A. Konkle et al.
BLOOD (2015)
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu et al.
BLOOD (2014)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
A. Gringeri et al.
HAEMOPHILIA (2013)
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
L. A. Valentino et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
A. Gringeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment
LG Mantovani et al.
HAEMOPHILIA (2005)
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
MD Tarantino et al.
HAEMOPHILIA (2004)
Health status and health-related quality of life associated with hemophilia
RD Barr et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Share Paper
